Delving into the Latest Updates on Sildenaifl Citrate with Synapse

Overview

Basic Info

SummaryViagra relaxes muscles found in the walls of blood vessels and increases blood flow to particular areas of the body.Viagra is used to treat erectile dysfunction (impotence) in men. Another brand of sildenafil is Revatio, which is used to treat pulmonary arterial hypertension and improve exercise capacity in men and women. This page contains specific information for Viagra, not Revatio. Sildenafil acts by blocking phosphodiesterase 5 (PDE5), an enzyme that promotes breakdown of cGMP, which regulates blood flow in the penis. It requires sexual arousal to work. It also results in dilation of the blood vessels in the lungs. Pfizer originally discovered the medication in 1989 while looking for a treatment for heart-related chest pain. It was approved for medical use in the United States and in the European Union in 1998.

Drug Type

Small molecule drug

Synonyms

Pahtension, Revatio, Revatio OD

+ [46]

Target

PDE5A

Action

inhibitors

Mechanism

PDE5A inhibitors(Phosphodiesterase 5A inhibitors)

Therapeutic Areas

Respiratory DiseasesUrogenital DiseasesOther Diseases+ [5]

Active Indication

Idiopathic pulmonary arterial hypertensionHypertension, PulmonaryFamilial Primary Pulmonary Hypertension+ [9]

Inactive Indication

Chronic heart failureDigital ulcerGangliosidosis, GM1+ [20]

Originator Organization

Pfizer Inc.

Active Organization

Zhejiang Jiangbei Pharmaceutical Co. Ltd.Upjohn EESVViatris Pharmaceutical GK

+ [22]

Inactive Organization

Pfizer Inc.

iX Biopharma Ltd.

Kyukyu Pharmaceutical Co., Ltd.

+ [1]

License Organization

Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Daré Bioscience, Inc.Beatrice Korea Co., Ltd.

+ [11]

Drug Highest PhaseApproved

First Approval Date

United States (27 Mar 1998),

Erectile Dysfunction

RegulationOrphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Orphan Drug (Japan), Orphan Drug (South Korea), Overseas New Drugs Urgently Needed in Clinical Settings (China)

Login to view timeline

Structure/Sequence

Molecular FormulaC28H38N6O11S

InChIKeyDEIYFTQMQPDXOT-UHFFFAOYSA-N

CAS Registry171599-83-0

The main objective of this study is to assess pharmacokinetics features of IV sildenafil in neonates with hypoxic-ischemic encephalopathy and treated by controlled hypothermia. This phase 2 study will prepare a large phase 3 randomized controlled trial to demonstrate the superiority of a combinatory therapy associating IV sildenafil and controlled hypothermia compared to Placebo and controlled hypothermia, on survival without brain lesions on MRI at discharge, in neonates born after 36 weeks of gestation.

Start Date01 Oct 2026

Sponsor / Collaborator

Assistance Publique des Hôpitaux de Paris SA

NCT07508358

/ Not yet recruitingPhase 1

Vaginal Sildenafil for Primary Dysmenorrhea: A Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover Mechanistic Study

This phase 1 randomized, double-blind, placebo-controlled, two-period crossover trial will evaluate whether a single 100 mg vaginal sildenafil citrate suppository reduces uterine hypercontractility during menstruation in adults with moderate-to-severe dysmenorrhea. Uterine contractility will be measured using cine magnetic resonance imaging (MRI). Key secondary objectives are to evaluate acute menstrual pain reduction over 4 hours, characterize limited systemic exposure using a single 4-hour plasma sildenafil concentration, and assess short-term safety and tolerability.

Start Date01 May 2026

Sponsor / Collaborator

Endeavor Health

NCT07039760

/ Not yet recruitingEarly Phase 1IIT

An Early Phase 1 Study of Asciminib With or Without Sildenafil for Brain Tumors

Dissemination of medulloblastoma is an independent risk factor of poor prognosis. Dissemination of medulloblastoma at recurrence is nearly universally fatal. ABL1 and 2 have been recently found to mediate the dissemination of medulloblastoma. Genetically inactivating ABL1 and 2 resulted in decreased leptomeningeal medulloblastoma and improved overall survival (OS) in rodent models. Asciminib is an FDA approved for the treatment of chronic myeloid leukemia and is well tolerated, likely due to its specificity for ABL1 and ABL2. Asciminib is a P-glycoprotein (P-gp) substrate and thus may be susceptible to being pumped out of tumor cells and brain endothelial cells. It is unclear if asciminib can enter the central nervous system (CNS) and brain tumors in adequate concentration to have anti-tumor effects.

Start Date30 Apr 2026

Sponsor / Collaborator

Washington University School of Medicine

100 Clinical Results associated with Sildenaifl Citrate

Login to view more data

100 Translational Medicine associated with Sildenaifl Citrate

Login to view more data

100 Patents (Medical) associated with Sildenaifl Citrate

Login to view more data

9,966

Literatures (Medical) associated with Sildenaifl Citrate

31 Dec 2026·RENAL FAILURE

Landscape of diabetic kidney disease drug clinical trials in China (2013–2023): global implications for innovation and policy

Review

Author: Xiao, Zheng ; Tan, Huifang ; Chen, Yinyin ; Zhu, Jiayu ; Li, Guoli ; Yang, Yiya

With the increasing prevalence of diabetes, the incidence rate of diabetic kidney disease (DKD) has risen yearly in China. While traditional therapies like renin-angiotensin system blockers remain foundational, the treatment paradigm is rapidly evolving with the emergence of novel agents, including SGLT2 inhibitors, mineralocorticoid antagonists, endothelin receptor antagonists, and GLP-1 receptor agonists. This study aims to provide an overview of the changing landscape of drug clinical trials on DKD in mainland China from 2013 to 2023. Detailed information of drug trials for DKD registered on the National Medical Products Administration Registration and Information Disclosure Platform for Drug Clinical Studies was collected. A total of 50 trials for DKD were included. Bioequivalence trials accounted for the most significant proportion (48%), followed by phase II (22%), phase I (20%), and phase III (10%). Chemical drugs accounted for the largest proportion (92%), followed by traditional Chinese medicine/natural medicine (8%). There were 18 different drugs involved in the 50 trials with Irbesartan (n = 24, 48%) ranked first in the number of trials. The parallel-group design was primarily used (48%), followed by crossover design (46%). Randomization was used by almost all trials (92%). Of all trials, 44 (88%) were launched domestically, whereas only 6 (12%) were international multi-center trials. Drug trials showed an uneven geographical distribution. Despite the progress in DKD drug clinical trials in mainland China during recent years, innovative drug research and development still has a long way to go. These findings provide an evidence base for optimizing global-regional alignment in DKD innovation policy.

01 Aug 2026·TALANTA

A systematically optimized two-dose differential strategy integrating stable isotope tracing and mass shift defect filtering for reducing false positives in high-resolution mass spectrometry–based drug metabolite profiling

Article

Author: Shih, Chia-Lung ; Yen, Meng-Chi ; Yang, Ji-Rui ; Li, Cai-Rong ; Chiou, Yi-Shiou ; Wang, Jie-Huei ; Lin, Chang-Te

Drug metabolite detection using metabolomics-based approaches is often challenged by high false-positive rates and the limited availability of authentic reference standards. In this study, we systematically optimized a data processing workflow that integrates a two-dose differential strategy with stable isotope tracing (SIT) and mass shift defect filter (MSDF) to improve the detection and confirmation of drug-related metabolites. Using isotopically labeled (D₀/D₃) compounds, metabolite features were confirmed based on MS/MS fragmentation profiles and characteristic isotopic mass shifts, providing indirect yet robust evidence for metabolite assignment. A total of 56 sildenafil-related metabolite features were putatively detected following MS/MS-based confirmation. Comparative analysis of three incubation setups revealed that the separated incubation setup consistently yielded the largest number of metabolite features, despite showing a relatively modest improvement in detection rate after MSDF incorporation. Notably, mixing D₀- and D₃-labeled compounds within the same incubation tube resulted in a marked reduction in metabolite detection, consistent with previous findings and underscoring the importance of experimental design in isotope-assisted metabolomics studies. The effects of key analytical parameters, including MSDF threshold, sample size, and retention time tolerance, were systematically evaluated. An MSDF window with an absolute deviation of <0.12 Da and a retention time tolerance of 0.2 min, with a sample size of three paired samples, were identified as optimal settings that balance detection rate and metabolite coverage. Overall, this work demonstrates a robust and scalable workflow for comprehensive drug metabolite profiling and provides practical guidance for optimizing metabolomics-based metabolite identification strategies in the absence of authentic reference standards.

01 Jun 2026·BIOCHEMICAL PHARMACOLOGY

Differential modulation of the sGC–cGMP pathway by sGC stimulators and activators in human lung cells

Article

Author: Cortijo, Julio ; Roger, Inés ; Ferrer-Gomez, Carolina ; Escrivá, Juan ; Montero, Paula ; Bayarri, María Amparo ; Milara, Javier

Chronic lung diseases are characterized by oxidative stress, inflammation, and fibroproliferation, conditions that impair nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic GMP (cGMP) signaling. Here, we investigated the differential effects of an sGC stimulator (riociguat) and an sGC activator (cinaciguat), alone or combined with the PDE5 inhibitor sildenafil, in primary human pulmonary cells exposed to cigarette smoke extract (CSE). Lung tissue from COPD and asthma patients displayed reduced sGC α1 and β1 expression, and CSE induced concentration-dependent oxidation of the sGC heme group, diminishing responsiveness to NO and to riociguat. Cinaciguat, but not riociguat, maintained cGMP production under oxidizing conditions, while co-treatment with sildenafil further increased cGMP levels for both drugs. In epithelial cells, fibroblasts, neutrophils, and endothelial monolayers, cinaciguat and riociguat attenuated CSE-induced oxidative stress, inflammatory cell adhesion, and profibrotic gene expression, with cinaciguat-particularly in combination with sildenafil-showing more robust effects across endpoints. These findings identify distinct pharmacodynamic profiles for sGC stimulators versus activators under oxidative conditions and support sGC modulation as a potential therapeutic approach in oxidative chronic lung diseases.

280

News (Medical) associated with Sildenaifl Citrate

14 Apr 2026

·www.prnewswire.com

Vella Bioscience Brings Precision to CBD With Pleasurewave™

Grounded in female arousal physiology, Vella's hero clinical‑grade arousal serum applies a more precise, performance‑led approach to CBD in intimate wellness NEW YORK, April 14, 2026 /PRNewswire/ -- Though conversations around women's pleasure are slowly opening up, the gap between awareness and access remains. Most "solutions" designed to support the full continuum of desire, arousal, and pleasure - particularly amid hormonal change - have yet to catch up. Dialogue alone is not enough: women need real, reliable solutions that support the full continuum of desire, arousal, and pleasure. This is where Vella Bioscience, the pioneering female health company built to address long-overlooked gaps in women's sexual wellness, has focused its work. At the core of this mission is Pleasurewave™, Vella's first clinical-grade arousal serum, which applies a precise, biology-led approach to CBD to support the physiological realities of female pleasure. Continue Reading Vella Bioscience's Pleasurewave As CBD has become increasingly associated with intimacy, particularly among women navigating hormonal transition, Vella uses a science-led approach grounded in biological intent, formulation discipline, and transparency over trend. CBD is often discussed as a single ingredient, yet its form and composition vary widely. Full-spectrum extracts can fluctuate significantly in CBD concentration and include secondary compounds without consistent purpose. Pleasurewave is formulated using CBD isolate, a highly purified form of cannabidiol processed to remove all other cannabinoids, plant material, waxes, and terpenes, leaving behind only pure CBD. This allows Vella to formulate with greater consistency and control. "We're at a moment where women are finally being invited into the conversation around pleasure, but they're still being underserved when it comes to solutions," said Carolyn Wheeler, Co-Founder and CEO of Vella Bioscience. "Pleasurewave was created to close that gap by giving women a more precise and reliable tool to support arousal and sensation, especially at times when their bodies may need more support." Pleasurewave contains CBD isolate and it is stabilized through Vella's proprietary biotech liposome system (LPTv1) process which works to maintain its stability over time, reflecting the company's research-driven approach to formulation. "Female arousal involves complex vascular and neurological processes," said Dr. Harin Padma-Nathan, Chief Medical Officer at Vella Bioscience. "Pleasurewave is designed to support these underlying mechanisms through targeted, localized delivery, helping enhance blood flow and sensory response where it matters most." The CBD isolate used in Pleasurewave contains no detectable THC, directly addressing common concerns around drug testing, stigma, and psychoactive effects. Vella's position is clear: intimacy should feel intentional, not tentative. Product Overview: Pleasurewave™ Pleasurewave ($55 MSRP) is a clinical-grade arousal serum engineered with Vella's patented liposomal delivery technology, designed to support female arousal through targeted, localized application, particularly when hormonal shifts impact blood flow, tissue responsiveness, and sensation. Pleasurewave uses Vella's liposomal delivery system to encapsulate CBD isolate, enhancing skin penetration and enabling delivery to smooth muscle and nerve-dense structures within the clitoral network. This localized delivery supports vasodilation and sensory responsiveness: two important physiological components of arousal. Nano-encapsulated CBD isolate is delivered to the smooth muscle beneath the skin, a critical but often overlooked aspect of arousal. By supporting healthy blood flow and relaxing this tissue, Pleasurewave helps restore the body's natural rhythm of sensation Free from cooling agents or numbing effects, the formula includes Vitamin E to soothe sensitive skin, monk fruit extract for antioxidant support, and a clean, oil-free, microbiome-friendly base designed for compatibility with condoms, toys, and daily intimacy. In clinical studies, 90% of participants reported improvement in at least one aspect of sexual pleasure, particularly among women navigating perimenopause, menopause, stress, or other hormonal shifts. "Pleasurewave plays a central role within the broader Vella portfolio," said Joy Allen-Altimare, President of Vella Bioscience. "It was designed to support a critical moment in a woman's experience when desire may be present, but the body needs assistance to respond. By offering targeted, reliable arousal support, Pleasurewave helps create greater confidence, connection, and ease in intimate experiences." Vella's Pleasurewave is available at select premium retailers such as Lemon Laine, Cos Bar, Amazon and at . About Vella Bioscience, Inc. Vella Bioscience, Inc. is a female health innovator dedicated to advancing women's sexual, hormonal, and intimate wellness through rigorous science and proprietary biotechnology. Built on scientific rigor and developed by the same team behind Viagra® and Cialis®, Vella addresses critical gaps in women's health research with products designed to empower women through education and evidence-based care. The company launched the category-first Vella Pleasure Serum, giving women unprecedented agency over their sexual experiences through a science-backed, hormone-free approach. To learn more, visit . MEDIA CONTACT: [email protected] SOURCE Vella Bioscience 21% more press release views with Request a Demo

10 Apr 2026

·www.prnewswire.com

Apomeds Enters the UK Market With Its Digital Healthcare Platform

WEYBRIDGE, England, April 10, 2026 /PRNewswire/ -- Apomeds has launched its digital healthcare platform in the United Kingdom, providing patients with online access to registered doctors and regulated pharmacies.The service is designed to improve access to care while offering a more tailored and convenient treatment experience for patients seeking discreet online healthcare, in line with rising demand for on-demand medical services. Continue Reading Apomeds Through Apomeds, patients complete a short medical questionnaire through a digital platform, reviewed by an experienced doctor. If clinically appropriate, Apomeds issues the prescription, which can be delivered by a registered pharmacy either through a 24-hour tracked courier or directly to a patient's chosen store. The platform offers patients an online healthcare marketplace, enabling patients to access licensed doctors and pharmacies through a digital-first care model. This UK launch forms part of a growing online marketplace that offers further efficacy in patient access to healthcare. Apomeds has already been operating in a number of international territories, such as Germany, Switzerland, Sweden, Denmark and Portugal, and has been recognised as a well-established online provider amongst patients. The UK market has actively supported its global growth plans. The commercial backdrop is substantial. One industry estimate for the UK telehealth market predicts it growing to more than $18.7billion in 2035. A number of drivers have been posited for this growth, including ongoing NHS digitization and increased patient demand for alternative treatment methods. Overall, these dynamics point toward an attractive opportunity for healthcare firms or digital providers looking to expand their presence. One of the existing indications that can also be addressed by the company's platform is erectile dysfunction. This is a large and well-established patient market that sees a high level of treatment demand. The NHS notes that erectile dysfunction is very common, particularly in men over 40, underlining the scale of the category in the UK. Through Apomeds, patients can have online consultations and, if suitable, get commonly prescribed treatments like sildenafil and tadalafil, all while ensuring privacy and convenience. Weight management offers access to a similarly strong growing sector. Demand for GLP-1 treatments such as Wegovy and Mounjaro has risen sharply, even as access in the UK remains limited and often costly. NHS England's staged rollout of tirzepatide helps explain why private and digital treatment pathways continue to draw interest. At the same time, the UK prescription weight-loss medication market is projected to grow from USD 421 million in 2025 to more than USD 2.4 billion by 2033, expanding at a CAGR of nearly 25%, underscoring the scale of the commercial opportunity. That demand is reinforced by broader health trends. The same UK weight loss medication market analysis reveals that a significant portion of England's adult population is overweight or obese, driving the demand for weight loss medications. This is fuelling demand for prescription-based treatment for weight management. As the clinical demand becomes stronger, we are seeing more digital platforms suggesting that they can act as gateways to both treatment provision and fulfillment. The platform follows a straightforward care pathway. Patients complete an online consultation, a doctor reviews the information and, if treatment is appropriate, issues a prescription. Medication is then dispensed by a partner pharmacy and delivered to the patient's home, offering a flexible and discreet alternative to more traditional access routes, particularly for patients who value speed, convenience and privacy. That model also reflects a broader shift toward more accessible treatment pathways that reduce friction in the patient journey. With exposure to two large and growing treatment categories, Apomeds is entering the UK at a time when more patients are embracing digital-first care. The launch strengthens the company's international footprint and positions it within a fast-expanding area of healthcare that continues to attract both consumer demand and investor attention, as online treatment pathways become a more established part of the wider healthcare market. It also gives the company entry into a market where convenience, discretion and treatment access remain key competitive factors. Contact: Email: support@apomeds.com Brand Website: Ibex House, 61 Baker Street, Weybridge, England Photo - SOURCE Apo Global Ltd. 21% more press release views with Request a Demo

08 Apr 2026

·www.biospace.com

Daré’s CEO Wants Everyone To Invest in Women’s Health, Starting With Her Company

iStock, Mary Long As Daré Biosciences approaches a pivotal year with a key product launch ahead, the company kicked off an open public offering, providing a chance for individuals to get involved for as little as $250. Sabrina Martucci Johnson wants everyone to invest in her women’s health biotech Daré Bioscience. That means you, dear reader. “We’ve been trying for a long time to close that gap between 1% of private healthcare investment that goes into companies like ours that are developing products for conditions solely affecting women,” Johnson, the company’s CEO, told BioSpace in a recent interview. And so, as Daré approaches a critical year with several product launches to come, the company in January kicked off a regulation A offering , providing a chance for individuals to get involved for as little as $250. Daré is officially seeking to raise $24.3 million with the offering.The idea has been picking up traction, according to Johnson. “It just seemed like the time to do something a little bit unusual,” said. While Johnson means everyone, she really wants to target women—particularly women who would be Daré’s customers. The biotech is developing multiple therapeutics for conditions that solely affect women, such as menopause, vaginal health, female fertility and more. Many of these indications do not have FDA-approved options, Johnson explained. Business Top 5 VC Raises by Women-Founded Biopharmas Venture capital flow to women-founded companies has stabilized in the post-pandemic environment. BioSpace looks back at five companies that have nabbed the most over the past two decades. December 3, 2025 · 6 min read · Annalee Armstrong Read more “I do feel a responsibility, in part, to build this movement and build this moment and do something that everyday investors can be a part of, because I do think that’s part of what it’s going to take to change the paradigm,” Johnson said. If women “vote with their wallets,” as Johnson says, larger, institutional investors may follow. And maybe, just maybe, that 1% number will climb and more biotechs launch to develop therapeutics targeting conditions that affect women. A Cultural Moment Daré previously collaborated with Organon to launch Xaciato, a gel to treat bacterial vaginosis. But now, several other products are nearing the market and the biotech will go it alone. The first is DARE to PLAY sildenafil cream, a topical treatment for female sexual arousal disorder. Other products include the consumer-focused probiotics DARE to RESTORE and the non-hormonal intravaginal ring birth control DARE to RECLAIM. Johnson said the GLP-1 revolution has set a perfect stage for Daré, as women become increasingly involved in their health via less traditional means. “Women are very motivated healthcare consumers. Most of the GLP-1 prescriptions are to women,” Johnson said. “That speaks to everything we’ve been saying for a long time about women’s health. Women want solutions. They will find solutions.” C-suite The 5 Most Powerful Women in Biopharma As the industry loses one of its key female leaders in GSK CEO Emma Walmsley, BioSpace profiles the women leading the industry’s smaller biopharmas. October 8, 2025 · 6 min read · Annalee Armstrong Read more Daré has provided early access to the products via compounding. With a more formal launch of sildenafil ahead, the company is tapping into social media and digital offerings, which is where women tend to seek access to treatments these days. The goal is to build trust and to provide clarity and specific, science-backed solutions for women. “From a cultural moment perspective, it’s a great time for us to be doing this,” Johnson said. If Daré’s offering is successful, women will take an even more active role in their health by becoming investors. The offering was specifically designed to be accessible to anyone. The terms are clearly explained without industry jargon. Johnson hopes that Daré’s work can help inspire new women’s health companies, particularly in therapeutics. “It is painful when I think that we are, to our knowledge, still the only publicly traded company working broadly and solely on women’s health therapeutics. When you think about the fact that we’re half the population, that there are so many things that we are going to experience simply because we’re assigned female at birth.” She continued, “There should be—just like, there’s hundreds and whatever of oncology companies—there should be hundreds of women’s health companies.” .responsive-container { display: flex; flex-wrap: wrap; border: 1px solid #ededed; font-family: Helvetica, Arial, Sans-Serif; padding: 20px 20px 10px 20px; } .column-left { flex: 1; max-width: 45%; padding: 20px 20px 10px 20px; } .column-right { flex: 2; padding: 20px 20px 10px 20px; } @media (max-width: 768px) { .column-left, .column-right { max-width: 100%; flex: 100%; padding: 10px 0; } } Subscribe to BioPharm Executive! Market insights, trending business and policy stories for biopharma leaders hbspt.forms.create({ region: "na1", portalId: "4413123", formId: "7c139b3c-ff0b-44e0-bffe-f449801dca59", onFormSubmitted: function($form, data) { window.dataLayer = window.dataLayer || []; window.dataLayer.push({ 'event': 'GTMevent', 'event_name': 'newsletter_sign_up' }); } });

100 Deals associated with Sildenaifl Citrate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D02229	Sildenaifl Citrate	G04BE03	DB00203

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Idiopathic pulmonary arterial hypertension	European Union	Viatris, Inc.	15 Sep 2016
Idiopathic pulmonary arterial hypertension	Iceland	Viatris, Inc.	15 Sep 2016
Idiopathic pulmonary arterial hypertension	Liechtenstein	Viatris, Inc.	15 Sep 2016
Idiopathic pulmonary arterial hypertension	Norway	Viatris, Inc.	15 Sep 2016
Hypertension, Pulmonary	Japan	Viatris Pharmaceutical GK	25 Jan 2008
Familial Primary Pulmonary Hypertension	European Union	Upjohn EESV	28 Oct 2005
Familial Primary Pulmonary Hypertension	Iceland	Upjohn EESV	28 Oct 2005
Familial Primary Pulmonary Hypertension	Liechtenstein	Upjohn EESV	28 Oct 2005
Familial Primary Pulmonary Hypertension	Norway	Upjohn EESV	28 Oct 2005
Pulmonary arterial hypertension associated with congenital heart disease	European Union	Upjohn EESV	28 Oct 2005
Pulmonary arterial hypertension associated with congenital heart disease	Iceland	Upjohn EESV	28 Oct 2005
Pulmonary arterial hypertension associated with congenital heart disease	Liechtenstein	Upjohn EESV	28 Oct 2005
Pulmonary arterial hypertension associated with congenital heart disease	Norway	Upjohn EESV	28 Oct 2005
Pulmonary arterial hypertension associated with connective tissue disease	European Union	Upjohn EESV	28 Oct 2005
Pulmonary arterial hypertension associated with connective tissue disease	Iceland	Upjohn EESV	28 Oct 2005
Pulmonary arterial hypertension associated with connective tissue disease	Liechtenstein	Upjohn EESV	28 Oct 2005
Pulmonary arterial hypertension associated with connective tissue disease	Norway	Upjohn EESV	28 Oct 2005
Pulmonary Arterial Hypertension	United States	Viatris Specialty LLC	03 Jun 2005
Erectile Dysfunction	United States	Viatris Specialty LLC	27 Mar 1998

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Heart Failure	Phase 3	Canada	Pfizer Inc.	12 Mar 2018
Hypoxic respiratory failure	Phase 3	United States	Viatris, Inc.	05 Aug 2013
Hypoxic respiratory failure	Phase 3	Belgium	Viatris, Inc.	05 Aug 2013
Hypoxic respiratory failure	Phase 3	Canada	Viatris, Inc.	05 Aug 2013
Hypoxic respiratory failure	Phase 3	Denmark	Viatris, Inc.	05 Aug 2013
Hypoxic respiratory failure	Phase 3	France	Viatris, Inc.	05 Aug 2013
Hypoxic respiratory failure	Phase 3	Germany	Viatris, Inc.	05 Aug 2013
Hypoxic respiratory failure	Phase 3	Italy	Viatris, Inc.	05 Aug 2013
Hypoxic respiratory failure	Phase 3	Netherlands	Viatris, Inc.	05 Aug 2013
Hypoxic respiratory failure	Phase 3	Norway	Viatris, Inc.	05 Aug 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03142568 (SIL02, CTgov)	Phase 2	Bronchopulmonary Dysplasia	109	sildenafil (Sildenafil Cohort 1)	szzrjmmmtk = yqpxjrpfbz nprtguyhgh (unrpldqlfy, oiezcfalvc - tlyrlxunya) View more	-	11 Mar 2026
				sildenafil (Sildenafil Cohort 2)	szzrjmmmtk = ebkpusltrb nprtguyhgh (unrpldqlfy, iylnuaupqd - iyvhumnypd) View more
NCT05669885 (Pubmed \| Cephalalgia)	Not Applicable	Post-Traumatic Headache	21	Sildenafil 100 mg	qtsgjsqefw(aihaxfoebp) = umvoczoixt ctpdgysifu (mqptnsoumk )	Positive	01 Mar 2026
				Placebo	qtsgjsqefw(aihaxfoebp) = gvqyiofghj ctpdgysifu (mqptnsoumk )
NCT04447989 (SILDI-SAFE, CTgov)	Phase 2	Bronchopulmonary Dysplasia	125	sildenafil (Cohort 1, Sildenafil)	ytzsnsswtx = hwkdhjcevp abohsvzehf (ewiuijqsid, pmcwmfxzoe - zhevxdzyft) View more	-	26 Jan 2026
				sildenafil (Cohort 2, Sildenafil)	ytzsnsswtx = kiugtwnpyz abohsvzehf (ewiuijqsid, glmresvppa - rigjkzuves) View more
NCT04356716 (CTgov)	Phase 2	Age Related Macular Degeneration \| Ischemia \| Central Serous Chorioretinopathy ... View more	22	Ocular Coherence Tomography-Angiography (OCT-A)+sildenafil	tzpintvvpx(xwrdkahrjg) = gwvkjldyyh pmpfkckgsy (ekurquyquo, 0.21) View more	-	04 Jul 2025
ATS2025	Not Applicable	Pulmonary Arterial Hypertension	-	Macitentan	frvgrhtkbp(rwrasvxwmf) = Macitentan and Bosentan had statistically significant ROR of deaths when compared to Ambrisentan frzjpjzcry (kcznvlnhgn ) View more	-	16 May 2025
				Bosentan
NCT00972569 (NCT00972569, Pubmed \| Circ Heart Fail)	Phase 1/2	Heart Failure cGMP	67	Low-dose intravenous BNP (0.005 µg/kg per minute)	lrvyveeeba(selbeganys) = fchwtoqbpo yspdjujkvo (wqyjkctewi, -14.6% - +9.4%) View more	Negative	01 Dec 2024
				Combination BNP/PDEV inhibition with sildenafil (25 mg q12 hours)	lrvyveeeba(selbeganys) = bsyweuphtd yspdjujkvo (wqyjkctewi, -5.3% - +18.8%) View more
NCT04948151 (Literature) Manual	Phase 2	Sexual Dysfunctions, Psychological	193	sildenafil	mhdqsyxnkm(fftuglmzaf) = etvqwfqpgu tirdfnjjpn (qacbvzkdwe ) View more	Positive	31 Jul 2024
				Placebo	mhdqsyxnkm(fftuglmzaf) = tjbihydcic tirdfnjjpn (qacbvzkdwe ) View more
NCT03199612 (SToPClot, CTgov)	Early Phase 1	Thrombosis \| Hemolysis	20	Sildenafil (Sildenafil)	vfwkocqccu(wjdtmezyio) = tmggdseefl ggoftntvgr (hiqcndisjk, bwhsrdpmyp - lsekmpvjuh) View more	-	10 Jul 2024
				Placebo Oral Tablet (Placebo Oral Tablet)	vfwkocqccu(wjdtmezyio) = uiszotgoqx ggoftntvgr (hiqcndisjk, zumntawkfz - gaakhblxsb) View more
NCT03855332 (OxHARP Trial, Pubmed \| Circ Res)	Phase 2	Cerebral Small Vessel Diseases	75	Sildenafil 50 mg	ogzzivtcph(nomwwoyzpf) = hwvrdhkuzq zvphxxwjlw (klnydvueqt, 0.5 - 3.15) View more	Positive	05 Jul 2024
NCT04948151 (Literature \| Pubmed \| Obstet Gynecol) Manual	Phase 2	Sexual Dysfunctions, Psychological	-	Sildenafil	gyxavfmuzw(uajrsafrnp) = hqczumzbsl anhswvhhpo (qyxiscibrw, 0.62)	Positive	18 Jun 2024
				Placebo	gyxavfmuzw(uajrsafrnp) = gbxjgjdzxg anhswvhhpo (qyxiscibrw, 0.04)